RxDoctor Payments Data

Michael Langiulli, MD

Cardiovascular Disease · Monroe, LANPI 1992765440

Payments from drug & device makers

$7,584in general payments, 2019–2025

Across 275 payments — averaging $27.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$2K
  • Novartis$650
  • Abbott$319
  • Merck$281
  • Sanofi-aventis U.S. LLC$258
  • plus $2K from 35 others

What the payments were for

  • Travel & lodging$2,76937%
  • Food & beverage$4,81063%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,584 in reported general payments places this provider in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$340,943
Medicare patients
903
Services billed
4,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban554$436,927
CamzyosMavacamten34$279,667
EntrestoSacubitril/Valsartan144$139,131
XareltoRivaroxaban120$90,408
JardianceEmpagliflozin28$22,994
Repatha SureclickEvolocumab40$22,336
BrilintaTicagrelor37$21,397
FarxigaDapagliflozin Propanediol24$15,190
NexlizetBempedoic Acid/Ezetimibe28$11,750
Metoprolol Succinate614$9,107
Valsartan291$7,533
Dofetilide11$7,469
Atorvastatin Calcium604$6,896
Rosuvastatin Calcium249$4,067
Nebivolol Hcl68$3,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$72$436,927554 claims
E.r. Squibb & Sons, L.L.C.Camzyos$191$279,66734 claims
NovartisEntresto$650$139,131144 claims
Johnson & JohnsonXarelto$215$90,408120 claims
AstraZenecaBrilinta, Farxiga$137$36,58761 claims
Boehringer IngelheimJardiance$105$22,99428 claims
Esperion Therapeutics, Inc.Nexlizet$149$11,75028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →